Coleman, R., de Boer, R., Frassoldati, A., Campbell, I., Paija, O., Martin, N., Modi, A., Bundred, N., Eidtmann, H., Llombart, A., Davidson, N., Neven, P., von Minckwitz, G., Sleeboom, H. P., Forbes, J., Barrios, C.. Oxford University Press; 2013. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results.

Zdenkowski, N., Forbes, J. F., Mann, G. B., Coates, A. S., Gebski, V., Davies, L., Thornton, R., Reaby, L., Cuzick, J., Green, M., Boyle, F. M., Kannourakis, G., Gill, P. G., Bayliss, E., Saunders, C., Della-Fiorentina, S., Kling, N., Campbell, I.. Oxford University Press; 2016. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial.